ArticleEuropean archives of psychiatry and clinical neuroscience2023
Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis.
Article in European archives of psychiatry and clinical neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer's disease: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Pooled it
- Are diagnostic technologies for alzheimer's disease and dementia cost-effective? A systematic review of economic evaluations.Alzheimer's research & therapy · 2026Pooled it
- The EEG analysis and identification of Alzheimer's disease: a review.Frontiers in aging neuroscience · 2025Pooled it
- Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment.Applied health economics and health policy · 2024Pooled it
- Cost analyses of plasma p-tau217 versus p-tau217/Aβ42 ratio using two-step approach in the Japanese health care system.The journal of prevention of Alzheimer's disease · 2026Article
- Precision pathways: optimising amyloid PET for sustainable Alzheimer's disease care.Journal of neurology · 2026Review
- CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression.medRxiv : the preprint server for health sciences · 2026Article
- The adherence of memory clinics to consensus recommendations for dementia diagnosis: A multicentric study in Italy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma amyloid-β predicts amyloid-β accumulation in PET A- non-demented participants.Journal of Alzheimer's disease : JAD · 2026Article
- Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms: Tau-enriched and Tau-scarce cohorts for cost-effective clinical use.Alzheimer's research & therapy · 2026Article
- Plasma biomarkers, brain amyloid-beta pathology, and cortical thickness in a non-Hispanic White and Black/African American middle-aged community cohort: The HCP-CoBRA study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Diagnostic performance of Alzheimer's disease blood and CSF biomarkers in a Brazilian cohort with low educational attainment.Molecular psychiatry · 2025Article
- Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study.European archives of psychiatry and clinical neuroscience · 2025Article
- The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment.BMC complementary medicine and therapies · 2025Article
- Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospective observational study.Alzheimer's research & therapy · 2025Observational
- Incremental value of amyloid PET in a tertiary memory clinic setting in China.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals.Alzheimer's research & therapy · 2024Article
- Predicting Alzheimer's disease CSF core biomarkers: a multimodal Machine Learning approach.Frontiers in aging neuroscience · 2024Article
- ChatGPT and BCI-VR: a new integrated diagnostic and therapeutic perspective for the accurate diagnosis and personalized treatment of mild cognitive impairment.Frontiers in human neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aimed at determining the cost-effectiveness of amyloid-positron emission tomography (PET) compared to Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid-β
Indexed as
Identifiers
35710952What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.